Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

This phase 2, open-label, multicenter study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas. The primary end point was objective response rate (ORR). Key secondary end points included safety, corr...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood
मुख्य लेखकों: Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2014
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425442/
https://ncbi.nlm.nih.gov/pubmed/24652992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-542142
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन